Liu Yi - Kura Oncology Insider

Kura Oncology Inc -- USA Stock  

USD 14.1  0.3  2.08%

Co-Founder, Chief Scientific Officer

Dr. Yi Liu, Ph.D. is Chief Scientific Officer of Kura Oncology, Inc. Since March 2015. Dr. Liu cofounded Prior Kura in August 2014 and served as the Chief Scientific Officer of Prior Kura from October 2014 until the Upstream Merger in March 2015. Prior to that, Dr. Liu cofounded and served as Chief Scientific Officer of Wellspring Biosciences LLC, a private biopharmaceutical company, from July 2012 to September 2014. Dr. Liu also cofounded Intellikine, Inc., a private biopharmaceutical company, where he served as Vice President of Drug Discovery from 2007 to May 2012, until its acquisition by Takeda Pharmaceutical Company Limited. Prior to Intellikine, Dr. Liu was the head of the drug design group at the Genomics Institute of the Novartis Research Foundation. Earlier in his career, he held senior scientist positions at both SGX Pharmaceuticals, Inc., a public biopharmaceutical company which was acquired by Eli Lilly and Company in 2008, and Curagen Corporationrationration, a public biopharmaceutical development company
Age: 46  Founder Since 2015      
858-500-8800  http://www.kuraoncology.com
Liu received his Ph.D. in Biochemistry from Princeton University, his MSc in computational chemistry from Beijing University and his BE in Chemical Engineering from Tsinghua University.

Management Efficiency

The company has return on total asset (ROA) of (27.36) % which means that it has lost $27.36 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (52.12) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 7.36 M in liabilities with Debt to Equity (D/E) ratio of 16.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Kura Oncology Inc has Current Ratio of 10.56 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Entity Summary

Kura Oncology, Inc., a clinical stage biopharmaceutical company, engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. Kura Oncology Inc (KURA) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 24 people. Kura Oncology is listed under Pharmaceutical Products category by Fama And French industry classification.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Kura Oncology Inc to your portfolio

Top Management

Kura Oncology Inc Leadership Team
Troy Wilson, Chairman
Steven Stein, Director
Heidi CPA, CFO
Thomas Malley, Director
JD Wilson, Chairman
Faheem Hasnain, Director
Annette North, President
Liu Yi, Founder
Pingda Ren, SVP, Ph.D
Antonio Gualberto, Executive, Ph.D
LLB Esq, SVP
Heidi Henson, CFO
Yi Liu, Executive
Robert Hoffman, Director, CPA

Stock Performance

Kura Oncology Performance Indicators